Axcelis Technologies

ACLS · NYSE · Technology · United States

Financials at a glance

Source: SEC XBRL

Annual

FY2023FY2024FY2025$1.1B$1.1B$1.0B$1.0B$839.0M$839.0M14.3% margin14.3% marginRevenueNet margin

Quarterly · last 8

Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26$252.4M$252.4M$256.5M$256.5M$256.6M$256.6M$192.6M$192.6M$194.5M$194.5M$213.6M$213.6M$199.0M$199.0M$215.2M$215.2M10.8% margin10.8% marginRevenueNet margin

Revenue (FY2025)

$839.0M

Net margin

14.3%

ROE

11.6%

Revenue CAGR (2y)

-13.9%

Profit CAGR (2y)

-30.1%

EPS (FY2025)

3.80

Net profit (FY2025)

$120.2M

Ask MarketChacha about ACLS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

  • Aug 4, 2026

    Axcelis rose on news of the successful evaluation closure of its Purion XEmax high-energy implanter at a leading semiconductor foundry, a positive customer validation ahead of its Q2 earnings release scheduled for Aug 6.

    source 1· confidence: high
  • Jul 29, 2026

    No specific company catalyst or filing was identified for the move; ACLS declined alongside recent sector/market weakness noted in coverage.

    · confidence: low
  • Jul 28, 2026

    Axcelis shares fell with the broader semiconductor sector amid a selloff, with no company-specific catalyst or new filing identified for the move.

    source 1source 2· confidence: low
  • Jul 27, 2026

    ACLS fell sharply with no company-specific news or filing today; the decline aligns with a broader semiconductor sector selloff (Philadelphia Semiconductor Index in bear market territory) amid mixed recent analyst notes and no fresh guidance.

    source 1source 2· confidence: medium
  • Jul 24, 2026

    Axcelis Technologies (ACLS) fell 5.24% with no named company-specific catalyst in filings or credible coverage; recent articles have highlighted valuation concerns ahead of Q2 results expected in August.

    · confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

PeriodRevenueNet profitEPSNet marginROE
FY2025$839.0M$120.2M3.8014.3%11.6%
FY2024$1.0B$201.0M6.1519.7%19.8%
FY2023$1.1B$246.3M7.4321.8%28.5%

Quarterly

PeriodRevenueNet profitEPSNet margin
2026Q2$215.2M$23.3M0.7510.8%
2026Q1$199.0M$9.2M0.304.6%
2025Q3$213.6M$26.0M0.8312.2%
2025Q2$194.5M$31.4M0.9816.1%
2025Q1$192.6M$28.6M0.8814.8%
2024Q3$256.6M$48.6M1.4918.9%
2024Q2$256.5M$50.9M1.5519.8%
2024Q1$252.4M$51.6M1.5720.4%
2023Q3$292.3M1.99
2023Q2$274.0M1.86
2023Q1$254.0M$47.7M1.4318.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.